A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

What Was Tested

This registered phase 3 trial tested Semaglutide.

Equivalence tests were performed for the percentage (%) of weight loss at 44w relative to baseline at the primary endpoint.

It had two arms (groups): TQF3510 (experimental) and Wegovy® (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 408 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18-70 years old, gender is not limited;. Body mass index (BMI) ≥ 28 kg/m2;. Self-report at least one unsuccessful diet and weight loss history;. Patients must give informed consent to this study before the trial and sign the informed consent voluntarily.

The full record lists 4 inclusion and 32 exclusion criteria; among the exclusions: have a history of diabetes of any type;; patients who had used any hypoglycemic drugs within 90 days before screening;; personal or first-degree relatives have a personal or family history of thyroid c-cell tumor or multiple endocrine tumor syndrome type 2;.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Semaglutide study did not mask who received what.

It started in 2025-03-20 with completion listed for 2026-03-07.

It ran at 66 sites in China (66).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage (%) of body weight loss (time frame: Baseline to week 44).

It also tracked 2 secondary outcomes, for example Waist circumference change from baseline.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 408 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.